This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Here's Why You Should Consider Buying Jazz Pharmaceuticals' Stock
by Zacks Equity Research
Here, we discuss some reasons why buying JAZZ stock now may turn out to be a prudent move.
SNYNegative Net Change AZNNegative Net Change LLYPositive Net Change JAZZPositive Net Change
pharmaceuticals
STTK Discontinues Cancer Program, Plans Workforce Cut, Stock Falls
by Zacks Equity Research
Shattuck stock plunges as it discontinues the clinical development of SL-172154 for two blood cancer indications and plans to reduce the workforce by 40%.
BMYNegative Net Change ANIPPositive Net Change FULCPositive Net Change STTKNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Here's Why You Should Add ALNY Stock to Your Portfolio Right Now
by Zacks Equity Research
Alnylam's Amvuttra and Givlaari sales continue to boost revenues. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.
REGNPositive Net Change ALNYPositive Net Change NVSNegative Net Change RHHBYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Zacks Investment Ideas feature highlights: Coca-Cola, Pfizer and Altria
by Zacks Equity Research
Coca-Cola, Pfizer and Altria have been highlighted in this Investment Ideas article.
KOPositive Net Change PFENegative Net Change MOPositive Net Change
pharmaceuticals
Should You Buy AbbVie Stock After Recent Parkinson's Study Success?
by Kinjel Shah
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
NVONegative Net Change LLYPositive Net Change ABBVNegative Net Change GMABNegative Net Change
pharmaceuticals
PRME Stock Rises 11.8% on Collaboration With Bristol Myers
by Zacks Equity Research
Prime Medicine collaborates with Bristol Myers Squibb for the development of T-cell therapies. Shares gain.
BMYNegative Net Change PRMENo Net Change KRYSPositive Net Change FULCPositive Net Change
biotechnology cell-therapy medical pharmaceuticals
AstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded Use
by Zacks Equity Research
The FDA grants priority review to AZN's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer. A decision is due in first-quarter 2025.
AZNNegative Net Change ANIPPositive Net Change KRYSPositive Net Change FULCPositive Net Change
pharmaceuticals
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
by Zacks Equity Research
Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty.
PFENegative Net Change MRNANegative Net Change ARCTPositive Net Change BNTXPositive Net Change
biotechnology biotechs medical pharmaceuticals vaccines
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors
by Zacks Equity Research
RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.
NVSNegative Net Change RHHBYNegative Net Change NVONegative Net Change LLYPositive Net Change
medical pharmaceuticals
Zacks.com featured highlights include GIII Apparel Group, Sonoco Products, Hamilton Insurance Group, Pampa Energia S.A. and Pfizer
by Zacks Equity Research
GIII Apparel Group, Sonoco Products, Hamilton Insurance Group, Pampa Energia S.A. and Pfizer are part of the Zacks Screen of the Week article.
PFENegative Net Change SONNegative Net Change PAMPositive Net Change GIIINegative Net Change HGNegative Net Change
consumer-discretionary industrial-products insurance pharmaceuticals utilities
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
by Zacks Equity Research
Sanofi and Regeneron's Dupixent becomes the first biologic treatment approved for COPD in the United States.
REGNPositive Net Change SNYNegative Net Change PFENegative Net Change LLYPositive Net Change
pharmaceuticals
Bayer Reports Positive Safety Data on Parkinson's Disease Drug
by Zacks Equity Research
BAYRY's experimental Parkinson's disease drug continues to show a favorable safety profile in all 12 participants in the trial's high and low-dose cohorts at 24 months.
PFENegative Net Change LLYPositive Net Change BAYRYNegative Net Change
medical pharmaceuticals
AbbVie Seeks Approval for Lung Cancer Candidate Teliso-V
by Zacks Equity Research
ABBV submits a BLA for Teliso-V to the FDA for treating previously treated non-small cell lung cancer patients with c-Met overexpression.
ABBVNegative Net Change ANIPPositive Net Change KRYSPositive Net Change FULCPositive Net Change
pharmaceuticals
SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims
by Zacks Equity Research
Casava stock falls as the company agrees to pay a cumulative fine exceeding $40 million to settle misleading claims charges brought against it by the SEC.
ANIPPositive Net Change KRYSPositive Net Change SAVAPositive Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More
by Kinjel Shah
JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.
AZNNegative Net Change JNJNegative Net Change PFENegative Net Change MRKPositive Net Change LLYPositive Net Change
pharmaceuticals
ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal
by Zacks Equity Research
Data from a late-stage study shows that AbbVie's tavapadon reduced the burden of Parkinson's disease. The drug previously demonstrated efficacy as adjunctive therapy.
ABBVNegative Net Change ADMAPositive Net Change KRYSPositive Net Change BVSPositive Net Change
biotechs medical pharmaceuticals
Bayer Submits Application for Label Expansion of Prostate Cancer Drug
by Zacks Equity Research
BAYRY moves ahead with the submission of an application seeking approval of darolutamide in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.
REGNPositive Net Change PFENegative Net Change LLYPositive Net Change BAYRYNegative Net Change
biotechnology medical pharmaceuticals
Bristol Myers Stock Up on FDA Nod for Schizophrenia Treatment
by Zacks Equity Research
The FDA approves BMY's differentiated schizophrenia treatment for adults and broadens its diverse portfolio. Shares gain.
BMYNegative Net Change ABBVNegative Net Change KRYSPositive Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Toyota Motor, AstraZeneca, Chubb, Air T and Preformed Line Products
by Zacks Equity Research
Toyota Motor, AstraZeneca, Chubb, Air T and Preformed Line Products are part of the Zacks top Analyst Blog.
AZNNegative Net Change TMNegative Net Change CBPositive Net Change PLPCPositive Net Change AIRTNegative Net Change
auto-tires-trucks computers insurance pharmaceuticals transportation
BMEA Stock Up 9% as FDA Lifts Clinical Hold on 2 Diabetes Studies
by Zacks Equity Research
Biomea stock rises 9% after the FDA lifts clinical hold on two phase I/II studies evaluating the company's lead candidate, BMF-219, for diabetes.
ANIPPositive Net Change KRYSPositive Net Change FULCPositive Net Change BMEANo Net Change
biotechnology biotechs medical pharmaceuticals
Buy These 4 S&P 500 Year-to-Date Laggards With Solid Near-Term Upside
by Nalak Das
Four S&P 500 laggards of this year have double-digit upside left for the rest of 2024. These are: CCL, PFE, ZTS, TDY.
CCLPositive Net Change PFENegative Net Change TDYPositive Net Change ZTSPositive Net Change
aerospace medical pharmaceuticals travel-leisure
New Strong Sell Stocks for September 27th
by Zacks Equity Research
ASO, AVD and CVS have been added to the Zacks Rank #24 (Strong Sell) List on September 27, 2024.
CVSNegative Net Change AVDPositive Net Change ASONegative Net Change
pharmaceuticals
Top Stock Reports for Toyota, AstraZeneca & Chubb
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor Corp. (TM), AstraZeneca PLC (AZN) and Chubb Ltd. (CB), as well as two micro-cap stocks Air T, Inc. (AIRT) and Preformed Line Products Co. (PLPC).
AZNNegative Net Change TMNegative Net Change PSAPositive Net Change FISPositive Net Change CBPositive Net Change GOLDNegative Net Change PLPCPositive Net Change AIRTNegative Net Change
auto-tires-trucks computers insurance pharmaceuticals transportation
AstraZeneca Stock Up Almost 14% in 6 Months: Time to Buy?
by Kinjel Shah
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga are likely to drive sales. It has several candidates with blockbuster potential.
SNYNegative Net Change AZNNegative Net Change IONSPositive Net Change
pharmaceuticals
MRK's Keytruda Combo Fails in Phase III Colorectal Cancer Study
by Zacks Equity Research
The phase III KEYFORM-007 study, evaluating Merck's Keytruda plus favezelimab for treating metastatic colorectal cancer, fails to meet the primary endpoint.
PFENegative Net Change MRKPositive Net Change ANIPPositive Net Change FULCPositive Net Change
pharmaceuticals